Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity

(2012) Libuše Zatloukalová et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart

(2012) Balindiwe J N Sishi et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity

(2012) Séverine Gratia et al.   Journal of Proteomics

Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients

(2011) Heloisa Sawaya et al.   AMERICAN JOURNAL OF CARDIOLOGY

NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies

(2011) Alexander Sirker et al.   BASIC RESEARCH IN CARDIOLOGY

Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats

(2011) El-Sayed M. Ammar et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats

(2011) V. Ashutosh Rao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the Mitochondrial Permeability Transition: Cardiac Ischemia-Reperfusion Versus Carcinogenesis

(2011) Sabzali Javadov et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

The use of liposomal anthracycline analogues for childhood malignancies: A systematic review

(2011) E. Sieswerda et al.   EUROPEAN JOURNAL OF CANCER

Anthracycline cardiotoxicity

(2011) Pierantonio Menna et al.   Expert Opinion On Drug Safety

Proteomic insights into chronic anthracycline cardiotoxicity

(2011) Martin Štěrba et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity

(2011) Pavlína Hašková et al.   TOXICOLOGY

Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?

(2011) Ronald M. Witteles et al.   Heart Failure Clinics

Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction

(2010) M. Y. Maslov et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer

(2010) Fausto Petrelli et al.   ANTI-CANCER DRUGS

In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity

(2010) Anna Vávrová et al.   ARCHIVES OF TOXICOLOGY

Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy

(2010) Y. Zhao et al.   CANCER RESEARCH

Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury

(2010) Petra Bendova et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage

(2010) Carrie Anna Geisberg et al.   CURRENT HYPERTENSION REPORTS

Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: Anti-apoptosis and promoting angiogenesis

(2010) Ligang Zhou et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Scavenging Effects of Dexrazoxane on Free Radicals

(2010) Zhang Junjing et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study

(2010) Patric J. Jansson et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy

(2010) Rui A. Carvalho et al.   TOXICOLOGY

Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?

(2010) Joy M. Fulbright et al.   Current Oncology Reports

Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil

(2009) Rabaa M. Al-Rousan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro

(2009) Partha Mukhopadhyay et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)

(2009) R.C.F. Leonard et al.   BREAST

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

(2009) O Popelová et al.   BRITISH JOURNAL OF CANCER

Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy

(2009) Dirk Lebrecht et al.   CARDIOVASCULAR PATHOLOGY

The iron chelator Dp44mT does not protect myocytes against doxorubicin

(2009) Brian B. Hasinoff et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors

(2009) Yu Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice

(2009) Shiwei Deng et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

How mitochondria produce reactive oxygen species

(2008) Michael P. Murphy   BIOCHEMICAL JOURNAL

Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity

(2008) Jinping Gao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone

(2008) T Šimůnek et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardiotoxicity of Antitumor Drugs†

(2008) Pierantonio Menna et al.   CHEMICAL RESEARCH IN TOXICOLOGY

The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity

(2008) Pr̆emysl Mladĕnka et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity

(2008) Tomas Simunek et al.   HEMOGLOBIN

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane

(2008) Elly V. Barry et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

(2008) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY

Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide

(2008) Louise K. Charkoudian et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

(2008) Francisco Molina-Holgado et al.   JOURNAL OF NEUROCHEMISTRY

Investigation of the stability of aromatic hydrazones in plasma and related biological material

(2008) Petra Kovaříková et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

(2008) O. Popelova et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class

(2008) C. K. Lim et al.   MOLECULAR PHARMACOLOGY

THE ROLE OF BIOMARKERS IN THE EARLY DETECTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN CHILDREN: A Review of the Literature

(2008) Annelies M. C. Mavinkurve-Groothuis et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

(2008) Elke Martin et al.   TOXICOLOGY